Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study
James L. Alexander, Zhigang Liu, Diana Muñoz Sandoval, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 11, pp. 1005-1015
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients
James L. Alexander, Benjamin H. Mullish, Nathan Danckert, et al.
EBioMedicine (2023) Vol. 88, pp. 104430-104430
Open Access | Times Cited: 36
Third and Fourth Vaccine Doses Broaden and Prolong Immunity to SARS-CoV-2 in Adult Patients with Immune-Mediated Inflammatory Diseases
Michelle W. Cheung, Roya M. Dayam, Janna R. Shapiro, et al.
The Journal of Immunology (2023) Vol. 211, Iss. 3, pp. 351-364
Open Access | Times Cited: 23
Impact of Prior COVID-19 Immunization and/or Prior Infection on Immune Responses and Clinical Outcomes
Achilleas Livieratos, Charalambos Gogos, Karolina Akinosoglou
Viruses (2024) Vol. 16, Iss. 5, pp. 685-685
Open Access | Times Cited: 9
Effect of DMARDs on the immunogenicity of vaccines
Yannick van Sleen, Kornelis S. M. van der Geest, Anke Huckriede, et al.
Nature Reviews Rheumatology (2023) Vol. 19, Iss. 9, pp. 560-575
Closed Access | Times Cited: 18
XBB.1.5‐Adapted COVID‐19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS‐CoV‐2 JN.1 Variant in Patients With Inflammatory Bowel Disease
Simon Woelfel, Joel Dütschler, Daniel Junker, et al.
Alimentary Pharmacology & Therapeutics (2024)
Open Access | Times Cited: 5
The Incidence and Clinical Characteristics of COVID‐19 in Children With IBD During the Omicron Wave: A Single‐Center Experience in China
Rui Li, Peiyu Chen, Huiwen Li, et al.
Gastroenterology Research and Practice (2025) Vol. 2025, Iss. 1
Open Access
Vaccine adherence and adverse events of the SARS-COV vaccine in patients with inflammatory bowel disease
Francisca Isabelle da Silva e Sousa, Raiza Lima Silva, Cézar Nilton Rabelo Lemos Filho, et al.
Gastroenterología y Hepatología (English Edition) (2025) Vol. 48, Iss. 1, pp. 502202-502202
Closed Access
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study
Zhigang Liu, Kaixing Le, Xin Zhou, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 8, Iss. 2, pp. 145-156
Open Access | Times Cited: 24
Systemic and Mucosal Immunogenicity of Monovalent XBB.1.5-Adapted COVID-19 mRNA Vaccines in Patients with Inflammatory Bowel Disease
Simon Woelfel, Joel Dütschler, Daniel Junker, et al.
Vaccines (2024) Vol. 12, Iss. 7, pp. 774-774
Open Access | Times Cited: 4
Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study
Hilde S Ørbo, K. H. Bjørlykke, Joseph Sexton, et al.
RMD Open (2024) Vol. 10, Iss. 2, pp. e003545-e003545
Open Access | Times Cited: 3
Persistence of Antibodies Six Months after Three COVID-19 mRNA Vaccine Doses in Patients with Inflammatory Bowel Disease
Freddy Caldera, Luke J. Richard, Mazen Almasry, et al.
Inflammatory Bowel Diseases (2023) Vol. 29, Iss. 10, pp. 1662-1666
Open Access | Times Cited: 8
Robust SARS-CoV-2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatments
Eva Zhang, Thi H. O. Nguyen, Lilith F. Allen, et al.
Gut (2023), pp. gutjnl-329136
Open Access | Times Cited: 8
Anti-tumor necrosis factor therapy is associated with attenuated humoral response to SARS-COV-2 vaccines in patients with inflammatory bowel disease
Filipa Bordalo Ferreira, Maria Ana Rafael, Lúcia Coimbra, et al.
Vaccine (2023) Vol. 41, Iss. 26, pp. 3862-3871
Open Access | Times Cited: 8
COVID-19 Immunization Rates in Patients with Inflammatory Bowel Disease Worldwide: A Systematic Review and Meta-Analysis
Francesco Paolo Bianchi, Rossella Donghia, Rossella Tatoli, et al.
Vaccines (2023) Vol. 11, Iss. 10, pp. 1523-1523
Open Access | Times Cited: 8
A Practical Update on COVID-19 and Inflammatory Bowel Disease: COVID-19 Disease Risk and Vaccine Safety and Efficacy.
Trevor L. Schell, Freddy Caldera
PubMed (2024) Vol. 20, Iss. 2, pp. 88-97
Closed Access | Times Cited: 2
Systemic and T cell‐associated responses to SARS‐CoV‐2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS‐CoV‐2
Simon Woelfel, Joel Dütschler, Marius König, et al.
Alimentary Pharmacology & Therapeutics (2022) Vol. 57, Iss. 1, pp. 103-116
Open Access | Times Cited: 13
Impact of COVID-19 in individuals with and without pre-existent digestive disorders with a particular focus on elderly patients
Alfredo Papa, Marcello Covino, Sara Sofia De Lucia, et al.
World Journal of Gastroenterology (2023) Vol. 29, Iss. 26, pp. 4099-4119
Open Access | Times Cited: 7
Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine
Zhigang Liu, James L. Alexander, Kathy Weitung Lin, et al.
Gastroenterology (2022) Vol. 164, Iss. 2, pp. 300-303.e3
Open Access | Times Cited: 11
Patients’ perspectives on, experience with and concerns about crohn's disease: insights from Chinese social media
Shaopeng Sun, Yunhong Hu, Heng Li, et al.
BMC Gastroenterology (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 6
STAR SIGN study: Evaluation of COVID‐19 vaccine efficacy against the SARS‐CoV‐2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease
Simon Woelfel, Joel Dütschler, Marius König, et al.
Alimentary Pharmacology & Therapeutics (2023) Vol. 58, Iss. 7, pp. 678-691
Closed Access | Times Cited: 6
COVID-19 Vaccine Booster Shot Preserves T Cells Immune Response Based on Interferon-Gamma Release Assay in Inflammatory Bowel Disease (IBD) Patients on Anti-TNFα Treatment
Grazia Pavia, Rocco Spagnuolo, Angela Quirino, et al.
Vaccines (2023) Vol. 11, Iss. 3, pp. 591-591
Open Access | Times Cited: 5
Role of gastroenterologists and healthcare providers in promoting COVID-19 immunization among individuals with inflammatory bowel disease: A systematic review and meta-analysis on a global scale
Francesco Paolo Bianchi, Maurizio Polignano, Nicola Carella, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 1
T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study
Asia‐Sophia Wolf, K. H. Bjørlykke, Hilde S Ørbo, et al.
EBioMedicine (2024) Vol. 108, pp. 105317-105317
Open Access | Times Cited: 1
T follicular helper cell responses to SARS‐CoV ‐2 vaccination among healthy and immunocompromised adults
Mollie Ailie Acheson Boyd, Alexandra Carey Hoppé, Anthony D. Kelleher, et al.
Immunology and Cell Biology (2023) Vol. 101, Iss. 6, pp. 504-513
Open Access | Times Cited: 4
Reduced Serological Response to COVID-19 Booster Vaccine is Associated with Reduced B Cell Memory in Patients With Inflammatory Bowel Disease; VARIATION [VAriability in Response in IBD AgainsT SARS-COV-2 ImmunisatiON]
Jayne Doherty, Neil O’Moráin, Róisín Stack, et al.
Journal of Crohn s and Colitis (2023) Vol. 17, Iss. 9, pp. 1445-1456
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top